Modulation of dendritic cell lineages
US12410225B2 · kind B2 · utility
0Cited by
65References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Nov 7, 2019 |
| Grant date | Sep 9, 2025 |
| Priority date | — |
| Expiry date | Oct 20, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/74
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates, in part, to agents, chimeric proteins and chimeric protein complexes that bind a plasmacytoid dendritic cell (pDC), e.g. Clec4C and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the pDC, e.g. Clec4C, binding agents, chimeric proteins, or chimeric protein complexes and their use in the treatment of various diseases, including autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.